Novo Nordisk’s oral formulation of semaglutide—marketed as an oral Wegovy pill—saw prescription volumes ramp sharply in its early weeks on the market, with analysts reporting roughly a 500% week‑over‑week increase in the second week. Industry trackers noted prescriptions surpassed 18,000 in the product’s second full week. The rapid uptake highlights sustained demand for GLP‑1 therapeutics and intensifies competition in obesity pharmacotherapy.